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ABSTRACT 
Hot melt extrusion is a versatile continuous manufacturing process extensively investigated for its 
applications with production of oral solid dosage forms, the aim of this study was to venture the 
applicability of HME in continuous manufacturing of topical semi-solid ointment formulations. 
Novel combination of a topical corticosteroid (Triamcinolone Acetonide) and local anesthetic 
(Lidocaine hydrochloride) were selected to be formulated with a water-soluble ointment base 
consisting of PEG 4000, PEG 1500 and Propylene glycol after performing appropriate drug-
excipient compatibility studies. To determine the ratios of the solid to liquid components of the 
macrogol base, ‘quality by design’ approach was employed by using design of experiments for 
formulation selection. Three formulations were selected using texture (work of adhesion and 
stiffness), pH and drug content uniformity as critical quality attributes from the design space of 
the formulation. These three selected formulations were then produced by conventional fusion 
method and simultaneously by HME using a modified screw configuration. Produced ointments 
were subjected to further characterizations including texture analysis (work of adhesion and 
stiffness), pH, drug content uniformity of the formulations, differential scanning calorimetry and 
finally to exhibit the release profile of the formulation in vitro drug release testing was conducted. 
All the final formulations depicted characteristics parallel to the set Quality Target Product Profile. 
Moreover, Formulations prepared by HME displayed better texture, uniformity and drug release 
characteristics in contrast with conventionally prepared ointments and hence HME can be 
considered as a useful continuous manufacturing technique for semi-solid manufacturing. 
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CHAPTER I: INTRODUCTION 
Hot Melt Extrusion 
Hot melt extrusion is one of the most widely utilized techniques in the Plastic industry. It involves 
melting, mixing and conveying of raw materials using rotating twin screws at a suitable processing 
temperature. The process results in production of uniformly shaped product propelled out of the 
die[1]. HME has been exploited by several pharmaceutical industries and research groups for its 
versatility in the manufacturing of pharmaceutical products[2][3]. The technique has found 
application in production of amorphous solid dispersions for improving the solubility and hence 
bioavailability of BCS class II API[4], formulation of abuse deterrent formulations[5][6], Taste 
masking of geriatric and pediatric formulation[7][8], topical, trans dermal and trans mucosal drug 
delivery systems[9][10][11]. A key aspect of this process is ‘continuous manufacturing’ which reduces 
the time and resources invested in batch manufacturing and hence enhances the productivity and 
in turn efficiency of the process. In this research project, a manufacturing process using HME for 
the Continuous manufacturing of a topical semi-solid ointment formulation was optimized. To 
accomplish this, certain attributes of Quality by Design (QbD) which are extensively suggested by 
the regulatory bodies for a process or product development were used. Specifically, Design of 
Experiments (DoE) which is a statistical tool used to apply QbD was used for this research project.  
By employing HME for Ointment manufacturing several objectives were accomplished i.e. 
Attaining a high yield and minimizing material loss experienced during conventional
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manufacturing, reducing the manufacturing time which in turn reducing the contact time of 
thermolabile drugs with elevated temperature conditions and providing high shear and mixing 
conditions which improves the texture and uniformity of the formulation of the formulations.  
Active Pharmaceutical Ingredients  
For this research a combination of a local corticosteroid (Triamcinolone acetonide) and a local 
anesthetic (Lidocaine hydrochloride) which are responsible for the additive action against 
inflammation were used. It has also been shown by previous research that Lidocaine HCl improves 
the stability of Triamcinolone acetonide which enhances the shelf life of this combination[12].  
Triamcinolone acetonide is a synthetic acetonide salt of triamcinolone which is a synthetic 
glucocorticosteroid. The glucocorticoid  mimicking is responsible for its immunosuppressive and 
anti-inflammatory activity[13]. It controls or prevents inflammation by suppressing migration of 
polynuclear leucocytes and fibroblasts and reversing capillary permeability. Corticosteroids 
decrease inflammation by stabilizing leukocyte lysosomal membranes, preventing release of 
destructive acid hydrolases from leukocytes, inhibiting macrophage accumulation in inflamed 
areas, reducing leukocyte adhesion to capillary endothelium, reducing capillary wall permeability, 
reducing edema formation, decreasing complement components, antagonizing histamine activity, 
antagonizing release of kinin from substrates, reducing fibroblast proliferation, collagen 
deposition, and subsequent scar tissue 
formation[14].  
TAA is generally degraded into two main 
degradation products i.e. 2-aldehyde and 
17-carboxylic acid. Both are produced by 
Figure 1. Structure of Triamcinolone acetonide 
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oxidation reactions catalyzed by trace metals[15]. This makes 17-C substitution the main target for 
TAA degradation. HME protects and minimizes the exposure of the product to oxygen because of 
the enclosed processing conditions and minimal processing time. The Amide group present in 
Lidocaine HCl might have a role in protecting the C-17 substitution from oxidation. Hence, Co-
formulation of the two involved APIs leads to improved anti-inflammatory activity and enhanced 
stability of the formulation. The Melting range of TAA was found to be 273-275ºC which was 
followed by the degradation of the API. Hence the processing temperature selected was below the 
degradation temperature. The partial solubilization of TAA in the formulation gives sustained 
release of the API at the site of inflammation and hence might provide an enhanced relief from 
inflammation at the affected area. 
Lidocaine hydrochloride is the Hydrochloride salt of the topical anesthetic Lidocaine, an 
aminoethylamide and a prototypical member of the amide class anesthetics.  Lidocaine interacts 
with voltage-gated Na+ channels in the nerve cell membrane and blocks the transient increase in 
permeability of excitable membranes to Na+. This prevents the generation and conduction of nerve 
impulses and produces a reversible loss of sensation. Lidocaine hydrochloride also exhibits class 
IB antiarrhythmic effects. The agent decreases the flow of sodium ions into myocardial tissue 
especially on the Purkinje network during phase 0 of the action potential, thereby decreasing 
depolarization, automaticity and excitability[16]. 
The melting point of LDH was found to be 
73-75ºC and degradation temperature was 
above 150ºC, hence the processing 
conditions were maintained below the 
degradation temperature to ensure the 
Figure 2. Structure of Lidocaine hydrochloride 
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stability of the API. The solubility of LDH in Propylene glycol (aqueous phase) contributes to the 
uniform distribution of the drug in the formulation and immediate release from the formulation on 
application to give instant relieve from inflammation.  
Design of Experiments  
Quality is the measure of repeatability or reproducibility of a product or process in context with 
its expressed attributes. The pharmaceutical Quality by Design (QbD) is a systematic approach to 
development which begins with predefined objectives. It emphasizes on understanding product 
and process control by using the sound science of quality risk management [17 ][18]. The quality 
target product profile (QTPP) is generally accepted as a tool for setting the strategic foundation 
for drug development. In the case of semisolids following parameters are considered critical for 
the quality of the formulation [19][20]. 
Table 1. QTPP and CQA for 0.1% TAA and 2% LDH Ointment. 
Elements Target Justification CQA items 
Dosage Form Ointment Proprietary product 
requirements  
 
Route of 
Administration 
Topical Proprietary product 
requirements 
 
Dosage strength 
(TAA) 
0.1% Proprietary product 
requirements 
 
Dosage strength 
(LDH) 
2% Proprietary product 
requirements 
 
Dosage design Water soluble ointment 
with macrogol base with 
completely soluble LDH 
and partly soluble TAA 
Based on the 
physiochemical 
properties of the 
constituent API 
 
Appearance White, smooth, creamy 
texture with API dispersed 
in the cream base 
Patient acceptability   
Identification Positive for API (TAA and 
LDH) 
Needed for clinical 
effectiveness 
CQA 
Assay 90.0-110.0 % Needed for clinical 
effectiveness 
CQA 
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pH Between 6.2-6.8 for the 
stability of the formulation 
Stability and patient 
acceptability 
CQA 
Impurities No known impurities; 
unknown impurities NMT 
0.2%; total impurities 
NMT 0.2% 
Needed for safety CQA 
Homogeneity and 
uniformity of 
content 
Samples withdrawn from 
three regions of the 
container should be within 
90.0-110.0% of the label 
claim 
Needed for clinical 
effectiveness 
CQA 
Physical attributes 
Work of Adhesion 
 
 
 
Stiffness 
 
Consistency in work of 
adhesion to ensure 
adherence of the 
formulation to the skin 
 
A function of viscosity; 
should be consistent for 
uniform manufacturing, 
mass transfer and 
application 
 
Needed for patient 
acceptability and 
optimum activity. 
 
Patient acceptability  
 
CQA 
 
 
 
CQA 
In vitro release 
testing 
Rate of release of the drug 
with respect to the square 
root of time 
Needed for clinical 
effectiveness and a 
regulatory 
requirement. 
CQA 
Stability 3 month accelerated 
stability 
Clinical 
effectiveness 
 
 
Design of Experiments (DoE) is used to ensure the achievement of desired quality attributes in the 
formulation. Various designs and statistical methods are usually considered for designing products 
or processes. The variables in the product or process affecting the CQA can be determined and 
optimized using this tool. For the current project DoE was used to optimize the formulation 
components as they have a major effect on the physical attributes of the formulation i.e. work of 
adhesion and stiffness. For this a 16 run, randomized, I-optimal design for mixtures was selected 
as it gives a detailed idea of the interactions and effects of all the components in the 
formulations[18].  The I-optimal design minimizes the average variances of prediction and therefore 
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seems more appropriate for mixture experiments as compared to the commonly used D-optimal 
designs. Because I-optimal design provides minimum average variance and simultaneously 
provides the effects of all the components in the formulation on the CQA. It was ideal to employ 
it for this research project as the acquired data can be used for selection or prediction of optimized 
combination of the components which demonstrate the required attributes. 
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CHAPTER II: METHODOLOGY 
Materials  
Chemicals  
Triamcinolone acetonide (Frontier Scientific, Batch no. LH20Q91), Lidocaine hydrochloride (MP 
Biomedicals, LLC Batch no. Q9114), Polyethylene glycol 1500 (PEG 1500), Polyethylene glycol 
4000 (PEG 4000), Propylene glycol, GantrezTM MS 955 Aerosil®, dibasic potassium phosphate, 
monobasic sodium phosphate, dibasic sodium phosphate, HPLC grade Acetonitrile, Methanol and 
Deionized water were used for analysis. 
Equipment and auxiliaries 
11 mm Twin screw extruder (ThermoFisher Scientific), Waters alliance e2695 HPLC separation 
module and Waters 2489 UV system, Waters 600 controller, Waters 2487 UV/VIS detector, 
Waters 717 plus autosampler, Mettler Toledo InLab®Micro pH probe, Texture Analyzer model 
TA.XT2i (Texture Technologies Corp. /Stable Micro Systems) along with a 1-inch diameter (TA-
3), Cary 600 series Fourier transform infrared spectrometer, DSC (TA DSC 25), Varian 620-IR, 
FT-IR Imaging microscope, Franz-diffusion cells, Hanson 15 Immersion cells with tools, 
Phenomenex Luna® 5 µm C18(2) 100 Å, LC Column 250 x 4.6 mm, Hanson SR 8 plus dissolution 
test station, Hanson small volume assembly. 
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Methods 
Drug-Excipient compatibility studies 
 
Before proceeding to formulation development, it is of crucial importance to determine the Drug 
Excipient compatibility i.e. the physical and chemical stability of the drug product with the 
excipients on storage. Stability studies are usually performed to ensure the long-term stability of 
the formulation but determination of the suitability of excipients as a part of Preformulation studies 
is an essential part of formulation development. To determine the drug-drug and drug-excipient 
compatibility binary mixtures of the drug substances with each component of the designed 
formulations were prepared. For this 1:1 (w/w) ratio of drug-drug or drug-excipient were taken in 
a glass mortar and pestle. This mixture was triturated for 5 minutes, vortexed and samples from 
the bulk were analyzed using Cary 600 series Fourier transform infrared spectrometer, Agilent 
technologies (FT-IR). The prepared mixtures as defined in Table 2 were then transferred to 
scintillation vials and exposed to accelerated stability storage conditions (40±0.5ºC and 75±1 
%RH) for one month using a validated stability chamber and then analyzed using FT-IR[21][22].  
Table 2. Compositions of various vials exposed to accelerated stability storage conditions for the 
determination of drug-drug/drug-excipient compatibility. 
 
Vial code Components 
*TAA **LDH ***PEG Propylene glycol GantrezTM Aerosil® 
1 *  *    
2 *    *  
3 *     * 
4 * *     
5 *   *   
6  * *    
7  *   *  
8  *    *\ 
9  *  *   
(*Triamcinolone acetonide, **Lidocaine hydrochloride, ***1:1 ratio of PEG 4000 to PEG 1500) 
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Design of Experiments   
Quality by Design (QbD) is a systematic approach to development (manufacturing, formulation 
etc.) that begins with predefined objectives and emphasizes product and process understanding 
and process control, based on sound science and quality risk management. For semi solid 
formulations quality target profile includes parameters such as texture (work of adhesion, 
Spreadibility, viscosity, stiffness etc.), pH of the formulation, drug content uniformity and to 
prepare a formulation that fits all these requirements it is important to analyze the effects of 
concentrations and ratios of different components on these parameters. For this an I-optimal 
coordinate exchange, randomized, 16 runs design was selected which is ideal for mixtures using 
design expert 11 software with fixed amounts of drugs and Aerosil® and varying proportions of 
PEGs (PEG 1500 and PEG 4000), Propylene glycol and GantrezTM MS 955. These prepared 
formulations with compositions mentioned in table 3 were exposed to preliminary screening using 
Work of Adhesion, Stiffness and pH as response parameters such as texture and pH are the primary 
and essential requirements in a semisolid topical formulation. Further in the design, formulations 
F1 and F4; F2, F5 and F6; F9 and F10 have identical formulae which are introduced by the software 
to determine point prediction, i.e. predictability of the characteristics of a formula based on results 
obtained by the software. A design with good point prediction can help pinpoint exact amounts of 
components required for desirable characteristics. 
Table 3. I-optimal, coordinate exchange, randomized, 16 runs design with different compositions 
PEG, PG and GantrezTM. 
 
Formulation code *Propylene glycol (A) PEG (B) GantrezTM (C) 
F1 20.00 75.80 04.20 
F2 38.70 51.70 09.60 
F3 54.80 42.20 03.00 
F4 20.00 75.80 04.20 
F5 38.70 51.70 09.60 
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F6 38.70 51.70 09.60 
F7 55.90 29.10 15.00 
F8 31.90 65.10 03.00 
F9 72.80 20.00 07.20 
F10 72.80 20.00 07.20 
F11 28.40 56.60 15.00 
F12 65.40 31.60 03.30 
F13 38.70 51.70 09.60 
F14 45.50 39.50 15.00 
F15 64.50 20.50 15.00 
F16 20.00 65.00 15.00 
(*represents 1:1 ratio of PEG 1500 and PEG 4000; all formulations had 0.1% Triamcinolone 
acetonide and 2% Lidocaine hydrochloride which were fixed as per their prescription dose and 
0.2% Aerosil®)  
 
Manufacturing of selected formulations 
The ointment was produced using two manufacturing processes i) Fusion method ii) Hot melt 
extrusion. 
Fusion method (Conventional) 
All the required ingredients were carefully weighed and procured for preparation of the ointment. 
First PEG 1500 and PEG 4000 were transferred into a glass mortar and pestle and triturated for 5 
minutes. Then this mixture was transferred into a porcelain crucible which was placed on a hot 
plate maintained at a temperature of 65±5ºC. Simultaneously, Aerosil®, GantrezTM, Triamcinolone 
acetonide and Lidocaine hydrochloride were transferred into the liquid phase i.e. Propylene glycol 
with appropriate mixing. On complete melting of PEG the liquid phase was fused with it and this 
mixture was maintained at 65±5ºC for 5 minutes to equilibrate the temperature of the mixture. This 
mixture was transferred to a glass mortar and pestle and triturated until solidification and 
appearance of a clicking sound. The semisolid mass was then transferred into Ointment containers 
and stored under refrigerated conditions for further use. 
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Hot-melt extrusion (continuous manufacturing process) 
For the manufacturing of ointment with HME first, the volumetric feeder (Solid feed) and the 
peristaltic pump (liquid feed) were calibrated by preparing a calibration curve of weight dispensed 
per minute vs % output (feeder parameter) and weight dispensed per minute vs RPM of peristaltic 
pump. A modified screw design was selected for the processing of the ointment through HME[10].  
 
Figure 3. Modified screw design for manufacturing of the ointment formulation. 
 
The liquid feed was introduced from zone 3 of the 11 mm hot melt extruder (ThermoFisher 
scientific, 11 mm twin screw extruder). The screw design was modified (as shown in fig. 3) in 
such a way that the liquid feed and the solid feed were exposed to proper mixing by the 
incorporation of an extended mixing zone followed by a material conveying zone and a terminal 
mixing zone before ejection of the processed semisolid into the collecting unit. The physical 
mixtures of PEG 1500, PEG 4000, GantrezTM, Aerosil®, Triamcinolone acetonide and Lidocaine 
hydrochloride were prepared and introduced at a predetermined feed rate depending on the ratio 
of liquid to solid feed. Propylene glycol was introduced in zone 3 after 1 minute and 23 seconds 
(time taken for solid feed to reach zone 3 with an RPM of 100) of introducing solid feed. 
12 
 
Table 4. Processing parameters maintained for the manufacturing of ointment by Hot melt 
extrusion. 
 
Parameters Description 
Equipment Pharma 11mm twin screw extruder 
Screw design Modified 
Barrel temperature Zone 1-5 (65ºC) 
Zone 5-8 (40ºC) 
RPM 100 
Torque 0-3% 
 
pH 
pH of the skin is considered to be around 5.5 and hence acceptable semisolid formulations should 
have a pH ranging from 5.5-7.0 to be compatible with the skin. To determine the pH aqueous 
concentrations of 1%, 5% and 10% w/v of the ointments were prepared in water[10]. The pH of the 
solutions was analyzed using Mettler Toledo InLab®Micro pH probe (Electrolyte 3 mol/L KCl). 
pH was considered as a critical quality attribute for the screening of the ointments. 
Texture analysis 
For texture analysis, Texture Analyzer model TA.XT2i (Texture Technologies Corp. /Stable Micro 
Systems) along with a 1-inch diameter (TA-3), acrylic, cylindrical probe, and a soft matter kit (TA-
275) was used for the determination of texture properties i.e. the work of adhesion and stiffness[11] 
using the parameters mentioned in table 5. Soft matter fixture was filled with the product, and it 
was placed below the texture analyser’s probe. The test was performed by lowering the probe at 
the pre-test speed to the product surface. The probe produced an additional deformation of 2mm 
of the sample at the test speed of 0.50 mm/s after encountering the surface and sensing the trigger 
force. The probe then withdrew from the sample at the speed of 5.00 mm/s. The same procedure 
was repeated for each sample in triplicates after cleaning the probe and levelling the surface of the 
sample. These two parameters are a representative of the force required by the probe to penetrate 
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the mass of the sample semisolid (Stiffness) and the force and time required for the probe to 
withdraw from this mass of ointment (work of adhesion) which are recorded as peak positive force 
and area of the negative slope respectively.  
Table 5. Parameters and set values for the texture analysis of prepared semisolid formulations. 
 
Parameters Set values 
Test mode Compression 
Pre-test speed 0.50 mm/sec 
Test speed 0.50 mm/sec 
Post-test speed 5.00 mm/sec 
Target mode Distance 
Force 100.0 g 
Distance 2 mm 
Trigger type Auto 
Trigger force 5 g 
Hold time 5 sec 
Temperature Room temperature 
 
Drug-content uniformity 
Drug content uniformity was determined by dispersing 100 mg (Triamcinolone acetonide) 
equivalent of the sample withdrawn from three different regions of the ointment container into 100 
ml of Acetonitrile (common solvent for extraction Triamcinolone acetonide and Lidocaine 
hydrochloride) and this mixture was subjected to sonication to facilitate the solubilization of the 
API in the solvent [20]. After sonication the solution was subjected to centrifugation and 10 µl of 
aliquot was withdrawn and diluted up to 1 ml with Acetonitrile. The concentration was analyzed 
using Waters HPLC-UV (Waters corp.) system. For the analysis calibration curve of 
Triamcinolone ranging from 5-80 µg/ml and of Lidocaine hydrochloride ranging from 50-800 
µg/ml were used.  
Method of analysis 
For the analysis of Triamcinolone acetonide and Lidocaine hydrochloride simultaneously, Waters 
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alliance e2695 HPLC separation module and Waters 2489 UV system was used. An existing 
method was modified[23], and the modified method was evaluated for its Capacity Factor, 
Selectivity and Resolution[24]. Table 6 displays the parameters for the HPLC method used for the 
simultaneous measurement of the drug substances. 
Table 6. Parameters for the modified HPLC method. 
 
Parameters Set values 
Mobile Phase *Phosphate buffer (pH 6.8): Acetonitrile: 
Methanol (50:40:10) 
Column LC-18-DB, Stainless steel, 250 mm X 4.6 
mm, 5µ particle size 
Injection volume 20 µl 
Detection wavelength  **238 nm and 210 nm for Triamcinolone and 
Lidocaine respectively 
Flow rate  1 ml/min 
Retention time 
Lidocaine hydrochloride 
Triamcinolone acetonide 
 
6.4 minutes 
8.9 minutes 
Run time 12 minutes  
*prepared by adding 8.75 g of dibasic potassium phosphate in 1000 ml of water and the adjusting 
pH with O-phosphoric acid. 
**For instruments with two detector channels two wavelengths can be used for better limit of 
detection of Lidocaine hydrochloride. For single detector channels wavelength of 238 nm should 
be used. 
 
Differential scanning calorimetry  
Differential scanning calorimetry presents various exothermic and endothermic events occurring 
in the sample with an increase in temperature. These events could represent Tm (Melting point of 
crystalline substances), Tg (Glass transition of amorphous polymers), Polymorphism and 
degradation. For this study the  DSC (TA DSC 25) of PEG (1500 & 4000), Gantrez, Triamcinolone 
acetonide and Lidocaine hydrochloride at a ramp rate of 10ºC /min with the temperature ranging 
from 25ºC to 300ºC[10][11] was conducted. Followed by the generation of DSC profiles of these 
individual components, DSC of the formulations were performed to observe any degradation peaks 
15 
 
and assess the solubilization of the drug in formulation with a ramp rate of 20ºC/min to avoid the 
distortion of peaks due to the presence of Aerosil® in the formulation and the same heating range.    
In vitro release testing (IV-RT) 
In vitro release testing (IV-RT) is a critical quality attribute for semi-solid formulations which 
predicts the release kinetics of the drug substance from the product. For this study vertical Franz-
diffusion cells were used with suitable receiver media and release membrane. The protocol for 
release studies was optimized using the following procedure and steps[27]. 
Drug solubility studies 
To determine the composition of the release media, saturation solubilities of Triamcinolone 
acetonide was determined by mixing 10 mg of the drug substance in 2 ml of various aqueous media 
(mentioned in table 7) with varying composition using 2 ml centrifuge tubes (n=3). These mixtures 
were transferred to a mechanical shaker and subjected to continuous agitation at a rate of 70 RPM 
for 24 hours. Later the samples were subjected to centrifugation at 13000 RPM for 10 minutes. 
The supernatant was collected and transferred to HPLC vials for analysis. The concentration was 
determined using the mentioned method of analysis. Solubility studies for Lidocaine HCL were 
not necessary as the drug substance was freely soluble in all considered medias[26]. 
Table 7. Composition of various vials for solubility studies  
 
Sample no. Composition 
1 (a, b, c) Milli Q water 
2 (a, b, c) **0.1 M Phosphate buffer solution (pH 7.4) 
3 (a, b, c) 0.1 % v/v Tween 60 
4 (a, b, c) 0.1 % v/v PEG 400 
5 (a, b, c) 0.1 % w/v BrijTM 98 
6 (a, b, c) 0.1 % w/v BrijTM C-20 SO (AP) 
7 (a, b, c) 0.1 % w/v BrijTM S-20 SO (mM) 
8 (a, b, c) 0.1 % v/v BrijTM L4 LQ (AP) 
*9 (a, b, c) 0.2 % w/v BrijTM C-20 SO (AP) in PBS 
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*10 (a, b, c) 0.2 % w/v BrijTM S-20 SO (mM) in PBS 
*11 (a, b, c) 0.2 % v/v BrijTM L4 LQ (AP) in PBS 
*These samples were a part of the secondary screening for selection of the receiver media rest of 
the samples were used for preliminary screening. 
**0.1M PBS was prepared using Monosodium Phosphate, monohydrate (2.795g/l) and Disodium 
Phosphate, heptahydrate (21.37g/l). 
 
Membrane inertness testing 
This study was performed to select a membrane suitable for the release studies. For this study drug 
solutions of Triamcinolone acetonide (5µg/ml), Lidocaine hydrochloride (5µg/ml) and a 
combination of Triamcinolone acetonide & Lidocaine hydrochloride (5µg/ml) were prepared. 10 
ml of each solution was taken in centrifuge tubes and labelled respectively as described in table 8. 
Four selected membranes were cut into half. 0.5 ml of sample was withdrawn from the centrifuge 
tube before soaking the membrane. Then the membrane was soaked in the centrifuge tube and 
allowed to soak for 24 hours. After 24 hours, 1 ml of sample was withdrawn from each of the 
centrifuge tubes and the before and after samples were analyzed using HPLC. A suitable inert 
membrane would not absorb the drug from the drug solution. This study is performed to ensure no 
retention of the drug on the membrane during the release studies. 
Table 8. Composition of various sample tubes taken for analysis with respective membranes 
used for the membrane inertness studies. 
 
Sample no. Membrane Pore size Diameter Drug solution (5 µg/ml) 
1 Nylon 0.22 µm 47 mm TAA 
2 Sopor 0.20 µm 25mm TAA 
3 Tuffryn 0.45 µm 25 mm TAA 
4 Cyclopore 0.20 µm 25 mm TAA 
5 Nylon 0.22 µm 47 mm LDH 
6 Sopor 0.20 µm 25mm LDH 
7 Tuffryn 0.45 µm 25 mm LDH 
8 Cyclopore 0.20 µm 25 mm LDH 
9 Nylon 0.22 µm 47 mm TAA+LDH 
10 Sopor 0.20 µm 25 mm TAA+LDH 
11 Tuffryn 0.45 µm 25 mm TAA+LDH 
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12 Cyclopore 0.20 µm 25 mm TAA+LDH 
TAA=Triamcinolone acetonide; LDH=Lidocaine hydrochloride 
 
Membrane validation studies  
Three ointment formulations were prepared with the drug load of 50%, 100% and 200% of the 
label claim (0.1% Triamcinolone acetonide and 2% Lidocaine hydrochloride) and the membrane 
validation studies were performed using Franz-diffusion cells (1.77cm2). Rubber rings were used 
to mount the membrane, the receiver compartment was filled with 7 ml of suitable receiver media 
and a stir bar was inserted in the cell to facilitate diffusion. Before initiating the studies, the selected 
membrane was soaked in the release media for 30 minutes and then mounted on the cell. Weighed 
amounts of the ointment formulations were withdrawn and placed on the donor compartment 
above the membrane and the sample was covered with parafilm, the assembly of the cell is shown 
in fig.4. Receiver compartment was checked for air bubbles. 0.3 ml of the sample was drawn at 
six different timepoints (0.5, 1, 2, 3, 4, 5 hours) and analyzed in HPLC. This experiment was 
performed using 9 cells (n=3).  
 
Figure 4. assembly of a vertical Franz-diffusion cell[28]. 
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Table 9. Weight of the formulations placed in the individual cells 
 
Cell number Drug load (%) Weight of the sample (grams) 
1 50 0.75 
2 100 1.06 
3 200 1.05 
4 50 0.95 
5 100 0.83 
6 200 0.84 
 
Drug release testing 
After performing the solubility studies (to determine the release media), membrane inertness 
testing (to screen a suitable inert membrane) and membrane validation studies (to ensure that the 
membrane does not act as a rate limiting barrier), the release studies of the three optimized 
formulation prepared by both conventional and HME process were performed. Immersion cells 
(Hanson, 15 mm) and 150 ml capacity dissolution cells were employed to determine the release of 
the drugs from the formulations. Immersion cells can be used as an automated quality control tool 
in the in vitro release testing procedure as a modification of USP II dissolution apparatus (paddle 
type)[29]. To load the immersion cells with ointment, first the support ring was placed upside down 
(larger opening face up) and then the membrane was locked in between the orifice washer and the 
ointment washer in a way that the membrane has minimum wrinkles. The dose was then applied 
to the circular area in the middle of the ointment washer and spread evenly. The ‘O’ ring was 
placed on the washer and the glass washer was placed to seal the ointment compartment. The lock 
ring was then placed on the support ring and sealed using the hand tool. These immersion cells 
loaded with ointment formulations were then immersed in the dissolution vessels (inserted in the 
dissolution apparatus using a conversion kit) with 150 ml of receiver media. Suitable paddles were 
introduced to the cell and the temperature was adjusted to 32±0.1ºC (temperature of the skin). 1 
ml of the sample was isolated and replaced with media at pre-determined time points (0.5, 1, 2, 3, 
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4 and 5 hours). The collected samples were then estimated using the developed HPLC method for 
this combination of drug substances. 
 
 
Figure 5. a) Assembly of the dissolution apparatus and immersion, b) Packing of ointment into 
the immersion cell[30] 
a b 
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CHAPTER III: RESULTS AND DISCUSSION 
Drug-Excipient compatibility 
The binary mixtures prepared were exposed to FT-IR analysis to determine the physical (H-
bonding) or chemical interactions between API and Excipients.   
 
Figure 6. FT-IR of Triamcinolone acetonide with various excipients 
 
From fig. 6 it can be seen that triamcinolone has prominent peaks on 3330 cm-1 which is because 
of the ‘-OH’ stretching vibrations[31]. This is an important site of reaction and degradation for 
triamcinolone and the intactness or slight shift in the peak shows no or weak physical interactions 
in the compounds. Weak physical interactions like H-bonding are responsible for increasing the
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solubility and stability of the API in the formulation. It can be observed in excipients like PEG and 
PG having ‘-OH’ groups and interacting with the concerned API. A similar interaction was visible 
between TAA and LDH which could be the reason for enhanced stability of the API in presence 
of TAA. The potency of the API was retained after subjecting the binary mixtures for a 1-month 
accelerated stability which ensures the compatibility of the API with the selected excipients. 
Aerosil® displays strong intermolecular H-bonding which is responsible for the disappearance of 
the ‘-OH’ peak in the binary mixture.  
 
Figure 7.  FT-IR of Lidocaine hydrochloride with various excipients 
Fig. 7 shows the interactions of various excipients with LDH and similar to TAA, the potency of 
LDH remains the same after storage with the excipients. The FT-IR shows that LDH is having 
weak interactions with PEG, PG and Aerosil® which seem like weak H-bonding that don’t affect 
the stability of LDH but enhance the solubilization of LDH in the formulation. This is the reason 
for complete solubilization of LDH in the formulation. 
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Screening of formulations  
The preliminary screening was performed based on CQA(s) like Texture (work of adhesion, 
stiffness) and pH of the formulation as mentioned in table 10.  
Table 10. Preliminary screening of the formulations based on CQA 
Formulation code Work of adhesion Stiffness pH 
F1 529.28 3823.2 6.04 
F2 420.78 0834.7 6.11 
F3 147.03 0202.7 6.05 
F4 550.00 3820.0 6.25 
F5 452.80 0814.8 6.12 
F6 465.32 0792.6 6.11 
F7 049.68 0056.4 5.99 
F8 597.21 1059.8 6.21 
F9 020.73 0030.4 6.13 
F10 028.55 0021.9 6.13 
F11 460.58 0826.5 5.98 
F12 050.39 0051.9 6.33 
F13 473.44 0750.3 6.12 
F14 162.87 0193.4 5.92 
F15 027.76 0035.6 6.03 
F16 650.61 2038.2 5.98 
 
All the formulations had a varying ratio of PEG:PG:GantrezTM and on analyzing the statistics it 
was seen that there is a significant correlation between the components and their ratios on the 
work of adhesion and stiffness. 
Work of Adhesion 
Table 11. ANOVA of the tested formulation for work of adhesion 
Source Sum of 
Squares 
DF Mean 
Square 
F-Value P-Value Significance 
Model 24.40 05 04.88 189.01 < 0.0001 significant 
Linear Mixture 21.98 02 10.99 425.67 < 0.0001 
 
AB 01.53 01 01.53 059.37 < 0.0001 
 
AC 00.34 01 00.34 013.24 0.0045 
 
BC 00.43 01 00.43 016.66 0.0022 
 
Residual 00.26 10 00.03 
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Lack of Fit 00.19 05 00.04 03.30 0.1082 not 
significant 
Pure Error 00.06 05 00.01 
   
Cor Total 24.66 15 
    
 
Table 11 provides information about the impact of the ratios of the components on the work of 
adhesion of the formulation. The Model F-value of 189.01 implies the model is significant. There 
is only a 0.01% chance that an F-value this large could occur due to noise. P-values less than 
0.0500 indicate model terms are significant. In this case A, B, C, AB, AC, BC are significant 
model terms. Values greater than 0.1000 indicate the model terms are not significant. The Lack 
of Fit F-value of 3.30 implies that the Lack of Fit is not significant relative to the pure error. 
There is a 10.82% chance that a "Lack of Fit F-value" this large could occur due to noise. Non-
significant lack of fit is good as it displays that the model to fits.  
Table 12. Fit statistics for the design 
Fit statistics 
Std. Dev. 0.16 R² 00.9895 
Mean 5.23 Adjusted R² 00.9843 
C.V. % 3.07 Predicted R² 00.9689   
Adeq Precision 32.9603 
 
Table 12 shows that the Predicted R² of 0.9689 is in reasonable agreement with the Adjusted 
R² of 0.9843; i.e. the difference is less than 0.2. Adeq Precision measures the signal to noise ratio. 
A ratio greater than 4 is desirable. The ratio of 32.960 indicates an adequate signal and hence the 
model can be used to navigate the design space. 
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Table 13. Coefficients in terms of coded factors 
Component Coefficient 
Estimate 
df Standard 
Error 
95% CI 
Low 
95% CI 
High 
VIF 
A-PG 02.71 1 0.1596 02.36 03.07 004.37 
B-PEG 06.25 1 0.1202 05.98 06.51 002.88 
C-Gantrez -19.64 1 6.5300 -34.18 -05.10 473.40 
AB 03.78 1 0.4903 02.69 04.87 002.66 
AC 30.60 1 8.4100 11.86 49.33 190.38 
BC 33.72 1 8.2600 15.31 52.12 184.09 
 
The coefficient estimate (Table 13) represents the expected change in response per unit change in 
factor value when all remaining factors are held constant. The intercept in an orthogonal design is 
the overall average response of all the runs. The coefficients are adjustments around that average 
based on the factor settings. When the factors are orthogonal the VIFs are 1; VIFs greater than 1 
indicate multi-collinearity, the higher the VIF the more severe the correlation of factors. As a rough 
rule, VIFs less than 10 are tolerable. 
 
Figure 8. Two component mix plots with varying ratios of PEG and PG in the formulations 
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Figure 9. Predicted versus actual values of work of adhesion for the formulations 
Stiffness 
Table 14. ANOVA of the tested formulations for stiffness 
Source Sum of 
Squares 
df Mean Square F-value p-value Significance 
Model 45.4100 05 09.0800 306.07 < 0.0001 significant 
Linear 
Mixture 
44.6500 02 22.3200 752.29 < 0.0001  
AB 00.1236 01 00.1236 004.17 0.0686  
AC 00.5791 01 00.5791 019.52 0.0013  
BC 00.5966 01 00.5966 020.11 0.0012  
Residual 00.2968 10 00.0297    
Lack of Fit 
00.2361 05 00.0472 003.89 0.0811 
not 
significant 
Pure Error 00.0607 05 00.0121    
Cor Total 45.71 15     
The Model F-value of 189.01 (Table 14) implies the model is significant. There is only a 0.01% 
26 
 
chance that an F-value this large could occur due to noise. P-values less than 0.0500 indicate model 
terms are significant. In this case A, B, C, AB, AC, BC are significant model terms. Values greater 
than 0.1000 indicate the model terms are not significant. The Lack of Fit F-value of 3.30 implies 
the Lack of Fit is not significant relative to the pure error. There is a 10.82% chance that a "Lack 
of Fit F-value" this large could occur due to noise. Non-significant lack of fit is good as it displays 
that the model to fit. 
Table 15. Fit statistics for the design  
Fit statistics 
Std. Dev. 0.1723 R² 00.9935 
Mean 5.8200 Adjusted R² 00.9803 
C.V. % 2.9600 Predicted R² 00.9791   
Adeq Precision 46.4605 
 
The Predicted R² of 0.9689 shown in table 15 is in reasonable agreement with the Adjusted R² of 
0.9843; i.e. the difference is less than 0.2. Adeq Precision measures the signal to noise ratio. A 
ratio greater than 4 is desirable. The ratio of 32.960 indicates an adequate signal. This model can 
be used to navigate the design space. 
Table 16. Coefficients in terms of coded factors 
Component Coefficient 
Estimate 
df Standard 
Error 
95% CI 
Low 
95% CI 
High 
VIF 
A-PG 02.72 1 0.1711 02.3400 03.10 004.37 
B-PEG 08.12 1 0.1289 07.8300 08.41 002.88 
C-Gantrez -26.06 1 7.0000 -41.6500 -10.47 473.40 
AB 01.07 1 0.5257 -00.0985 02.24 002.66 
AC 39.83 1 9.0100 19.7400 59.91 190.38 
BC 39.71 1 8.8600 19.9800 59.44 184.09 
 
The coefficient estimates in table 16 represents the expected change in response per unit change 
in factor value when all remaining factors are held constant. The intercept in an orthogonal design 
is the overall average response of all the runs. The coefficients are adjustments around that average 
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based on the factor settings. When the factors are orthogonal the VIFs are 1; VIFs greater than 1 
indicate multi-collinearity and the higher the VIF the more severe the correlation of factors. As a 
rough rule, VIFs less than 10 are tolerable. 
 
Figure 10. Two component mix plots with varying ratios of PEG and PG in the formulations 
 
fig 10. Shows that stiffness of the formulation increases with an increase in the PEG concentration. 
This shows that the PEG and the PG concentrations have a significant effect on the stiffness of the 
formulation. Moreover formulation concentration for a desired stiffness can be predicted using the 
software because of the high degree of regression and fit statistics displayed in table 15 and fig 11. 
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Figure 11. Actual versus Predicted plot for the values of stiffness for various prepared 
formulations 
 
pH 
The pH of all the prepared formulations were within range. Though pH is considered as a CQA 
for this formulation and will be used for evaluation of the formulations, it was no longer considered 
a parameter for screening of the formulations as there was no significant correlation between the 
ointment components and pH. 
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Analytical Method Validation 
Four major descriptors are commonly used to report the characteristics of the chromatographic 
column, system and particular separation i.e. Retention factor/Capacity factor (k’), selectivity (α) 
and Resolution. 
Length of time taken by the retarded compound to pass through the column depends on its capacity 
factor. It is the measure of  degree to which an analyte partitions into the stationary phase from the 
mobile phase. This can be determined by using the following equation where tr is the retention 
time of the analyte and t0 is the retention time of the non-retained sample i.e. solvent front. 
𝑘′ =
𝑉𝑟 − 𝑉0
𝑉0
 
𝑘′ = (𝑡𝑟 − 𝑡𝑜)/𝑡0 
The capacity factor for TAA (k’TAA) was found to be 4.99 (solvent front was seen at 1.5 minutes 
and retention time of TAA is 8.99 minutes), for LDH (k’LDH) was found to be 3.26 (retention time 
of LDH was observed to be 6.4 minutes). A capacity factor between 1-5 is ideal for analysis. 
Selectivity (α) is the ability of the chromatographic system to discriminate between the two 
analytes and can be determined by taking a ratio of the capacity factors of the two analytes. 
∝=
𝑘𝑇𝐴𝐴
𝑘𝐿𝐷𝐻
 
α for the system was found to be 1.53 which is ideal for uninterrupted determination of two 
analytes. 
Finally, resolution of the system was determined using the following formulae. 
𝑅 = 2
𝑡𝑇𝐴𝐴 − 𝑡𝐿𝐷𝐻
𝑤1 + 𝑤2
 
The resolution of system should be ≥1.5 and the resolution for this system was found to be 6.4 
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which is an excellent resolution for determination. 
Optimization and Manufacturing processes 
After preliminary screening of the formulations, three formulations (F2, F3 and F8) with desirable 
properties were selected (Table 17) , manufactured using conventional and HME techniques and 
characterized for Uniformity of Drug Content, Differential Scanning Calorimetry, Hot Stage 
Microscopy and in vitro release testing.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12. Manufacturing process of Ointment formulations using HME 
Three formulations were selected for further characterization with different Stiffness and Work of 
Adhesion depending on the purpose of use. Formulation F2 was selected and intended for oral use 
i.e. ulcers, burns etc. Formulation F3 was selected for skin infections, burns and allergic 
manifestations because of better Spreadibility and Formulation F8 was selected for Hemorrhoids 
treatment because of its stiff and adhesive nature which enhances the retention time of the 
formulation and delays softening of the formulation which improves therapeutic efficiency and 
SOLID 
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patient compliance. 
Table 17. Selected formulations and their characteristics. 
Formulation 
code 
Work of 
Adhesion 
Stiffness pH Drug 
Content 
(TAA) 
Drug 
Content 
(LDH) 
F2C 498.223±52.988 0843.5600±30.67 6.11±0.04 098.9±0.017 107.9±1.018 
F2H 488.618±03.550 0865.4445±03.15 6.22±0.01 104.7±0.008 108.4±0.999 
F3C 159.808±27.460 0228.4200±25.77 6.05±0.07 108.5±0.002 106.6±0.954 
F3H 148.372±03.450 0215.5470±02.02 6.27±0.05 101.5±0.003 097.7±0.890 
F8C 615.104±68.780 1230.4500±80.26 6.21±0.03 095.3±0.010 101.3±1.090 
F8H 596.154±08.920 1014.6400±06.12 6.30±0.03 094.8±0.006 101.9±0.988 
C-Conventionally prepared; H-Hot-Melt Extruded. 
 
From the  above characterization of selected formulations, it can be observed that conventionally 
prepared ointments have a larger standard deviation as compared to the ointments prepared using 
HME. This could be due to the uncontrolled variables that participate in conventional 
manufacturing such as material loss during mixing, mass transfer, rate of mixing or temperature 
control during mixing which are in fact very well controlled during HME processing. During the 
Hot Melt Extrusion process, parameters such as feed rate, mixing RPM, processing temperature 
and torque are well under control which helps produce uniform products and minimize batch to 
batch variation. The pH of all the formulations (HME and Conventional) was within the specified 
range. All the formulations had drug content within the specified range and hence all the produced 
Ointments were accepted and subjected to further characterization. 
Differential scanning calorimetry 
All the prepared Ointments were characterized using DSC to ensure the solubility of the API in 
the formulation. The DSC plot shows complete disappearance of the drug peaks which suggests 
that either both the drugs have been dissolved in the base or that the increase in temperature during 
DSC experimentation has solubilized the drugs in the base. From the DSC curve shown in Fig. 13, 
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it can be seen that there has been complete solubilization of the drugs in the Ointment base both 
in 
HME and Conventionally prepared ointments. 
Figure 13. DSC profiles of pure API, excipients and prepared Ointment formulations. 
In vitro release testing (IV-RT) 
Based on the saturation solubility of TAA in various release media, 0.2 % w/v BrijTM C-20 SO 
(AP) in PBS was selected as it completely solubilized LDH and had the maximum solubility for 
TAA (Table 18) with respect to the other tested release mediums with different surfactants. 
Table 18. Solubilities of TAA in different release mediums. 
Sample number Solubility (µg/ml) 
1 Practically insoluble 
2 Practically insoluble 
3 3.65 
4 Practically insoluble 
5 3.44 
6 7.71 
7 7.30 
8 6.74 
9 9.08 
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10 6.63 
11 8.45 
Refer Table 7 for sample compositions 
Tuffryn 0.45µm, 25mm membrane was selected amongst the tested membranes because of its 
inertness to the API. There was negligible absorption of API on the membrane before and after 
exposure to the drug solution. 
Table 19. Membrane inertness studies. 
Sample number % Absorbed (TAA) % Absorbed (LDH) 
1 4.20 - 
2 2.89 - 
3 0.72 - 
4 2.44 - 
5 - 0.19 
6 - 0.59 
7 - 0.19 
8 - 0.19 
9 0.73 0.19 
10 0.43 0.39 
11 0.14 0.19 
12 3.21 0.58 
Refer Table 8 for sample composition 
 
From the other values it can be seen that the Tuffryn membrane absorbed the least amount of 
TAA and LDH from the drug solution which makes its use suitable for this study. 
Finally, to see if the release of the API from the formulation is not hindered by  the membrane 
and is proportional to the concentration of the drug in the formulation, membrane validation 
studies were conducted. 
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Figure 14. Membrane validation for TAA 
 
 
 
 
 
 
Figure 15. IV-RR versus dose strength of TAA 
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The membrane validation studies were performed using the topical product prepared at three 
strengths (50% of the label claim, 100% label claim and 200% label claim). The release profile 
(cumulative release versus square root of time) showed a linear profile as shown in figure 14 and 
16. Figures 15 and 17 shows the relationship between the dose strength and IV-RR (Slope of 
cumulative release versus square root of time). Liner correlation with excellent regression 
coefficient (>0.9) shows that the membrane could be used for performing the release studies of 
other formulations or form comparison of the formulated product with the reference product. The 
membrane is not acting as a rate controlling barrier and the release is absolutely attributable to the 
formulation properties.  
 
 
 
Figure 16. Membrane validation of LDH 
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Figure 17. IV-RR versus Dose strength of LDH 
 
Finally using the above selected release media, membrane release studies of the selected 
formulations were performed. It can be seen from the release studies that the formulations prepared 
by HME and the formulations prepared conventionally show comparable release rates. Moreover, 
formulations F2 and F8 show better release rates and profiles as compared to conventionally 
prepared formulation. This can be attributed to the enhanced and uniform mixing provided by Hot-
Melt extrusion which allows proper distribution and enhanced solubilization of TAA in the 
ointment base which is not achieved conventionally. F3H exhibits a similar release profile as 
compared to F3C, this could be because of a higher drug content in F3C as compared to F3H.  
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Figure 18. Drug release profile of TAA from F2H and F2C 
 
 
 
 
 
 
 
 
Figure 19. Drug release of LDH from F2H and F2C 
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Figure 20. Drug release profile of TAA from F3H and F3C 
 
 
 
 
 
 
 
Figure 21. Drug release profile of LDH from F3H and F3C 
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Figure 22. Drug release profile of TAA from F8H and F8C 
 
 
 
 
 
Figure 23. Drug release profile of LDH from F8H and F8C 
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CHAPTER IV: CONCLUSION 
A series of statistical and experimental characterizations were conducted to optimize the 
formulation and manufacturing variables for the production of three stable Ointment formulations. 
Drug-Excipient compatibility studies demonstrated the absence of drug-drug and drug-excipient 
interactions. Further, the I-optimal design provided a design space and platform which can be used 
for prediction of the excipient ratios for a target texture profile. Selected formulations were 
successfully manufactured using conventional and HME techniques. From the results of 
comparison between the conventional and HME ointment formulations, it can be concluded that 
HME shows a better control over the process variables and leads to the production of a more 
uniform product. It can also be concluded that the controlled processing variables lead to a reduced 
batch to batch variation and improved the consistency in the CQA(s) of the ointments. 
Simultaneously, a protocol to evaluate the in vitro release rates of formulations containing either 
TA, LDH or both were successfully developed and validated. 
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